HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute Cellular Rejection in ABO-Incompatible Renal Transplant Recipients Receiving Rituximab Is Associated with Delayed-Onset Neutropenia.

Abstract
BACKGROUND Rituximab induces long-lasting B cell depletion in the peripheral blood and increases the levels of proinflammatory cytokines associated with regulatory B cell depletion. Previous reports showed that B cell-related cytokine release after administration of rituximab may induce acute cellular rejection (ACR) and delayed-onset neutropenia. The present study was conducted to investigate the correlation between acute rejection and delayed-onset neutropenia in ABO-incompatible renal transplant recipients who underwent administration of rituximab for 1 year after transplantation. MATERIAL AND METHODS From June 2006 to July 2015, 47 patients with chronic renal failure received ABO-incompatible renal transplant with rituximab induction at Osaka City University Hospital. All 47 patients underwent plasmapheresis due to removal of anti-A/B antibodies and administration of rituximab, and their transplants were carried out successfully. We investigated the correlation between ACR and delayed-onset neutropenia in ABO-incompatible renal transplant recipients who underwent administration of rituximab for 1 year after transplantation. RESULTS Fourteen patients (29.8%) experienced ACR (group A), and 33 recipients did not develop ACR (group B). The frequency of delayed-onset neutropenia was higher in group A than in group B (p=0.0503). Multivariate logistic regression analysis revealed that the frequency of ACR correlated significantly with the prevalence of delayed-onset neutropenia. CONCLUSIONS Our results indicated that ACR in ABO-incompatible renal transplant recipients receiving rituximab was associated with delayed-onset neutropenia.
AuthorsJunji Uchida, Tomoaki Iwai, Shunji Nishide, Kazuya Kabei, Nobuyuki Kuwabara, Takeshi Yamasaki, Toshihide Naganuma, Norihiko Kumada, Yoshiaki Takemoto, Tatsuya Nakatani
JournalAnnals of transplantation (Ann Transplant) Vol. 22 Pg. 455-462 (Jul 25 2017) ISSN: 2329-0358 [Electronic] United States
PMID28740069 (Publication Type: Journal Article)
Chemical References
  • ABO Blood-Group System
  • Immunosuppressive Agents
  • Rituximab
Topics
  • ABO Blood-Group System (immunology)
  • Adolescent
  • Adult
  • Aged
  • Blood Group Incompatibility (complications, immunology)
  • Female
  • Graft Rejection (complications, immunology)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Kidney Failure, Chronic (surgery)
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Neutropenia (complications, immunology)
  • Plasmapheresis
  • Rituximab (therapeutic use)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: